All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Following a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting, the Lymphoma Hub was pleased to speak Grzegorz Nowakowski, Mayo Clinic, Rochester, US. We asked, What are the clinical implications of the ODAC vote for a favorable benefit/risk profile of polatuzumab vedotin for untreated diffuse large B-cell lymphoma (DLBCL)?
Clinical implications of the ODAC vote in favor of polatuzumab vedotin for untreated DLBCL.
Nowakowski discusses findings from the phase III POLARIX study (GO39942; NCT03274492) comparing polatuzumab vedotin plus R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisolone) with the current standard of care, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), in patients with previously untreated DLBCL. Nowakowski summarizes the data on progression-free survival, overall survival, and toxicities, referring to the heterogeneity of patients in this study. Finally, Nowakowski discusses polatuzumab vedotin in the context of current standard of care treatments and the global clinical impact this may have.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Using ctDNA analysis in risk profiling of frontline DLBCL: Results from the POLARIX study
In the risk profiling of previously untreated patients with DLBCL from the POLARIX study using ctDNA, results suggested that ctDNA analysis has prognostic...
Is peripheral neuropathy in patients with DLBCL more severe after pola-R-CHP vs R-CHOP treatment?
During the EHA 2022 Congress, the Lymphoma Hub spoke with Marek Trněný, Charles University, Prague, CZ. We asked, Is peripheral neuropathy in patients...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox